Progress in the understanding of the pathology and pathogenesis of cutaneous drug eruptions: Implications for management

American Journal of Clinical Dermatology

Volumn 4, Issue 6, 2003, Pages 407-428

  Crowson, A Neil ^a,c   Brown, Tricia J ^a   Magro, Cynthia M ^b  

^a UNIVERSITY OF OKLAHOMA   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c Regional Medical Laboratories   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMMONIUM CHLORIDE; ANALGESIC AGENT; ANTIHISTAMINIC AGENT; ANTIINFECTIVE AGENT; ANTIMALARIAL AGENT; AZATHIOPRINE; CALCIPOTRIOL; CHLORAMPHENICOL; CIMETIDINE; CORTICOSTEROID; CYCLOSPORIN; DAPSONE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; PSORALEN DERIVATIVE; QUINOLONE DERIVATIVE; RANITIDINE; SULFADIAZINE SILVER; SUNSCREEN;

BLISTER; CLINICAL FEATURE; CLINICAL TRIAL; DIFFERENTIAL DIAGNOSIS; DRUG ERUPTION; ECZEMA; ERYTHEMA MULTIFORME; ERYTHRODERMA; HISTOPATHOLOGY; HUMAN; IMMUNOGLOBULIN A DEFICIENCY; LICHENOID ERUPTION; PATHOGENESIS; PEMPHIGOID; PEMPHIGUS; PHOTOSENSITIVITY DISORDER; PRIORITY JOURNAL; PSEUDOPORPHYRIA; PUSTULE; REVIEW; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; URTICARIA; VASCULITIS;

DRUG ERUPTIONS; HUMANS; VASCULITIS;

EID: 0037973322     PISSN: 11750561     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128071-200304060-00005     Document Type: Review

References (176)

1. Arndt KA, Jick H. Rates of cutaneous reactions to drugs: a report from the Boston Collaborative Drug Surveillance program. JAMA 1976; 235: 918-22
2. Bigby M, Jick S, Jick H, et al. Drug-induced cutaneous reactions: a report from the Boston Collaborative Drug Surveillance Program on 15 438 consecutive inpatients, 1975-1982. JAMA 1986; 256: 3358-63
3. Jick H, Miettinen OS, Shapiro S, et al. Comprehensive drug surveillance. JAMA 1970; 213: 1455-60
4. Hunziker T, Kunzi UP, Braunschweig S, et al. Comprehensive hospital drug monitoring (CHDM): adverse skin reactions, a 20-year survey. Allergy 1997; 52: 388-93
5. Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Ann Rev Immunol 1989; 7: 145-73
6. Wierenga EA, Snoek M, Jansen HM, et al. Human atopic-specific types 1 and 2 T helper cell clones. J Immunol 1991; 147: 2942-9
7. van der Heijden FL, Wierenga EA, Bos JD, et al. High frequency of Il-4-producing CD4+ allergen-specific T lymphocytes in atopic dermatitis lesional skin. J Invest Dermatol 1991; 97: 389-94
8. Kay AB, Ying S, Varney V, et al. Messenger RNA expression of the cytokine gene cluster, Interleukin 3 (IL-3), IL-4, IL-5, and granulocyte/macrophage colony-stimulating factor, in allergen-induced late-phase cutaneous reactions in atopic subjects. J Exp Med 1991; 173: 775-8
9. Mosmann TR, Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today 1996; 17: 138-46
10. Lopez AF, Sanderson CJ, Gamble JR, et al. Recombinant human interleukin 5 is a selective activator of human eosinophil function. J Exp Med 1988; 167: 219-24
11. Britschgi M, Seiner UC, Schmid S, et al. T-cell involvement in drug-induced acute generalized exanthematous pustulosis. J Clin Invest 2001; 107: 1433-41
12. Britschgi M, Pichler WJ. Acute generalized exanthematous pustulosis, a clue to neutrophil-mediated inflammatory processes orchestrated by T cells. Curr Opin Allergy Clin Immunol 2002; 2: 325-32
13. Wintroub BU, Stern R. Cutaneous drug reactions: pathogenesis and clinical classification. J Am Acad Dermatol 1985; 13: 167-79
14. Magro CM, Crowson AN. Drug-induced immune-dysregulation as a cause of atypical cutaneous lymphoid infiltrates: a hypothesis. Hum Pathol 1996; 26: 125-32
15. Barranco VP. Clinically significant drug interactions in dermatology. J Am Acad Dermatol 1998; 38: 599-612
16. Crowson AN, Magro CM. The cutaneous pathology of lupus erythematosus. J Cutan Pathol 2001; 28: 1-23
17. Koopmans PP, van der Ven AJ, Vree TB, et al. Pathogenesis of hypersensitivity reactions to drugs in patients with HIV infection: allergic or toxic? AIDS 1995; 9: 217-22
18. Metry DW, Lahart CJ, Farmer KL, et al. Stevens-Johnson syndrome caused by the antiretroviral drug nevirapine. J Am Acad Dermatol 2001; 44: 354-7
19. Cohen AD, Friger M, Sarov B, et al. Which intercurrent infections are associated with maculopapular drug reactions? A case-control study. Int J Dermatol 2001; 40: 41-4
20. Aihara M, Sugita Y, Takahashi S, et al. Anticonvulsant hypersensitivity syndrome associated with reactivation of cytomegalovirus. Br J Dermatol 2001; 144: 1231-4
21. Descamps V, Valance A, Edlinger C, et al. Association of human herpesvirus 6 infection with drug reaction with eosinophilia and systemic symptoms. Arch Dermatol 2001; 137: 301-4
22. Sullivan JR, Shear NH. The drug hypersensitivity syndrome: what is its pathogenesis? Arch Dermatol 2001; 137: 357-64
23. Shear NH. Diagnosing cutaneous adverse reactions to drugs. Arch Dermatol 1990; 126: 94-7
24. Rieder MJ. Mechanisms of unpredictable adverse drug reactions. Drug Saf 1994; 11: 196-212
25. Rieder MJ. In vivo and in vitro testing for adverse drug reactions. Pediatr Clin North Am 1997; 44: 93-111
26. Barbaud AM, Bene M-C, Schmutz J-L, et al. Role of delayed type hypersensitivity and adhesion molecules in amoxicillin-induced morbilliform rashes. Arch Dermatol 1997; 133: 481-6
27. Bigby M. Rates of cutaneous reactions to drugs. Arch Dermatol 2001; 137: 765-70
28. Crowson AN, Magro CM. Recent advances in the pathology of cutaneous drug eruptions. Dermatol Clin 1999; 17: 537-60
29. Breathnach SM, Hintner H. Adverse drug reactions and the skin. Oxford: Blackwell Scientific Publication, 1992
30. Pichler W, Yawalkar N. Pathophysiology of drug-elicited exanthems. ACI Int 2000; 12: 166-70
31. Carr A, Vasek E, Munro V, et al. Immunohistochemical assessment of cutaneous drug hypersensitivity in patients with HIV infection. Clin Exp Immunol 1994; 97: 260-5
32. Yawalkar N, Shrikhande M, Hari Y, et al. Evidence for a role for IL-5 and eotaxin in activating and recruiting eosinophils in drug-induced cutaneous eruptions. J Allergy Clin Immunol 2000; 106: 1171-6
33. Yawalkar N, Hart Y, Frutig K, et al. T cells isolated from positive epicutaneous test reactions to amoxicillin and ceftriaxone are drug specific and cytotoxic. J Invest Dermatol 2000; 115: 647-52
34. Posadas SJ, Leyva L, Torres MJ, et al. Subjects with allergic reactions to drugs show in vivo polarized patterns of cytokine expression depending on the chronology of the clinical reaction. J Allergy Clin Immunol 2000; 106: 769-76
35. Hari Y, Urwyler A, Hurni M, et al. Distinct serum cytokine levels in drug- and measles-induced exanthemata. Int Arch Allergy Immunol 1999; 120: 225-9
36. Pichler WJ, Yawalkar N, Britschgi M, et al. Cellular and molecular pathophysiology of cutaneous drug reactions. Am J Clin Dermatol 2002; 3: 229-38
37. Yawalkar N, Pichler WJ. Pathogenesis of drug-induced exanthemata. Int Arch Allergy Immunol 2001; 124: 336-8
38. Yawalkar N, Hunger RE, Buri C, et al. A comparative study of the expression of cytotoxic proteins in allergic contact dermatitis and psoriasis: spongiotic skin lesions in allergic contact dermatitis are highly infiltrated by T cells expressing perforin and granzyme B. Am J Pathol 2001; 158: 803-8
39. Yawalkar N, Egli F, Hari Y, et al. Infiltration of cytotoxic T cells in drug-induced cutaneous eruptions. Clin Exp Allergy 2000; 30: 847-55
40. Crowson AN. Superficial and deep perivascular dermatitis. In: Barnhill R, Crowson AN, Busam K, Granter S, editors. Textbook of dermatopathology. New York: McGraw-Hill Co, 1998: 69-81
41. Greaves MW. Chronic urticaria. N Engl J Med 1995; 332: 1767-72
42. Weedon D. Cutaneous drug reactions. In: Weedon D, editor. The skin. Edinburgh: Churchill Livingston, 1992: 559-569
43. Zurcher K, Krebs A. Cutaneous drug reactions. Basel: Karger, 1992
44. Weedon D. The lichenoid reaction pattern: skin pathology. Edinburgh: Churchill Livingstone, 1997: 29-63
45. Bong JL, Lucke TW, Douglas WS. Lichenoid drug eruption with proton pump inhibitors [letter]. BMJ 2000; 320 (7230): 283
46. Russell MA, Langley M, Truett AP, et al. Lichenoid dermatitis after the ingestion of gold-containing liquor. J Am Acad Dermatol 1997; 36: 841-4
47. Crowson AN, Magro CM. Lichenoid and subacute cutaneous lupus erythematosus-like dermatitis associated with antihistamine therapy. J Cutan Pathol 1999; 26: 95-9
48. Magro CM, Crowson AN. Lichenoid and granulomatous dermatitis: a novel cutaneous reaction pattern. Int J Dermatol 2000; 39: 126-33
49. Crowson AN, Magro CM. Subacute cutaneous lupus erythematosus in the setting of calcium channel blocker therapy. Hum Pathol 1997; 28: 67-73
50. Young PC, Montemarano AD, Lee N, et al. Hypersensitivity to paclitaxel manifested as bullous fixed drug eruption. J Am Acad Dermatol 1996; 34: 313-4
51. Sigal-Nahum M, Konqui A, Gaulier A, et al. Linear fixed drug eruption. Br J Dermatol 1988; 118: 849-51
52. Mahoob A, Haroon TS. Drugs causing fixed eruptions: a study of 450 cases. Int J Dermatol 1998; 37: 833-8
53. Korkij W, Soltani K. Fixed drug eruption: a brief review. Arch Dermatol 1984; 120: 520-4
54. Teraki Y, Moriya N, Shiohara T. Drug-induced expression of intracellular adhesion molecule-1 on lesional keratinocytes in fixed drug eruption. Am J Pathol 1994; 145: 550-60
55. Shiohara T, Nickoloff BJ, Sagawa Y, et al. Fixed drug eruption. Expression of epidermal keratinocyte intracellular adhesion molecule-1 (ICAM-1). Arch Dermatol 1989; 125: 1371-6
56. Pelicano R, Lomuto M, Ciavarella G, et al. Fixed drug eruptions with feprazone are linked to HLA-B22. J Am Acad Dermatol 1997; 36: 782-4
57. Hamamoto Y, Ohmura A, Kinoshita E, et al. Fixed drug eruption due to clarithromycin. Clin Exp Dermatol 2001; 26: 48-9
58. Chan HL, Tan KC. Fixed drug eruption to three anticonvulsant drugs: an unusual case of polysensitivity. J Am Acad Dermatol 1997; 36: 259
59. Tham SN, Kwok YK, Chan HL. Cross-reactivity in fixed drug eruptions to tetracyclines. Arch Dermatol 1996; 132: 1134-5
60. Alanko K, Kanerva L, Mohell-Taloahti B, et al. Nonpigmented fixed drug eruption from pseudoephedrine. J Am Acad Dermatol 1996; 35: 647-8
61. Hindioglu U, Sahin S. Nonpigmented fixed drug eruption from pseudoephedrine hydrochloride. J Am Acad Dermatol 1998; 38: 499-500
62. Agnew KL, Oliver GF. Neutrophilic fixed drug eruption. Australas J Dermatol 2001; 42: 200-2
63. Selvaag E. Clinical drug photosensitivity: a retrospective analysis of reports to the Norwegian Adverse Drug Reactions Committee from the years 1970-1994. Photodermatol Photoimmunol Photomed 1997; 13: 21-3
64. Leenutaphong V, Manuskiatti W. Fenofibrate-induced photosensitivity. J Am Acad Dermatol 1996; 35: 775-7
65. Lowe NJ, Fakouhi TD, Sern RS, et al. Photoreactions with a fluoroquinolone antimicrobial: evening versus morning dosing. Clin Pharmacol Ther 1994; 56: 587-91
66. Roujeau JC, Bioulac-Sage P, Bourseau C, et al. Acute generalized exanthematous pustulosis. Arch Dermatol 1991; 127: 1333-8
67. Moreau A, Dompmartin A, Castel B, et al. Drug-induced generalized exanthematous pustulosis with positive patch tests. Int J Dermatol 1995; 34: 263-6
68. Katagiri K, Takayasu S. Drug induced acute generalized exanthematous pustulosis. J Dermatol 1996; 23: 623-7
69. Park WM, Kim JW, Kim CW. Acute generalized exanthematous pustulosis induced by itraconazole. J Am Acad Dermatol 1997; 36: 794-6
70. Blodgett TP, Camisa C, Gay D, et al. Acute generalized exanthematous pustulosis secondary to diltiazem therapy. Cutis 1997; 60: 45-7
71. Condon CA, Downs AMR, Archer CB. Terbinafine-induced acute generalized exanthematous pustulosis. Br J Dermatol 1998; 138: 706-23
72. Hall AP, Tate B. Acute generalized exanthematous pustulosis associated with oral terbinafine. Australas J Dermatol 2000; 41: 42-5
73. Bennett ML, Jorizzo JL, White WL. Generalized pustular eruptions associated with oral terbinafine. Int J Dermatol 1999; 38: 596-600
74. Rogalski C, Hurlimann A, Burg G, et al. Drug reaction to terbinafine simulating an acute generalized exanthematous pustulosis. Hautarzt 2001; 52: 444-8
75. Isogai Z, Sunohara A, Tsuiji T. Pustular drug eruption due to bacampicillin hydrochloride in a patient with psoriasis. J Dermatol 1998; 25: 612-5
76. Halevy S, Cohen A, Livni E. Acute generalized exanthematous pustulosis associated with polysensitivity to paracetamol and bromhexine: the diagnostic value of in vitro interferon-gamma release test. Clin Exp Dermatol 2000; 25: 652-4
77. Lazarov A, Livini E, Halevy S. Generalized pustular drug eruptions: confirmation by in vitro tests. J Eur Acad Dermatol Venereol 1998; 10: 36-41
78. Fye KH, Vrowley E, Berger TG, et al. Celecoxib-induced Sweet' s syndrome. J Am Acad Dermatol 2001; 45: 300-2
79. Thibault MJ, Billick RC, Srolovitz H. Minocycline-induced Sweet's syndrome. J Am Acad Dermatol 1992; 27: 801-4
80. Fukutoku M, Shimizu S, Ogawa Y, et al. Sweet's syndrome during therapy with granulocyte-colony stimulating factor in a patient with aplastic anemia. Br J Haematol 1994; 86: 645-8
81. Walker DC, Coehn PR. Trimethoprim-sulfamethoxazole-associated acute febrile neutrophilic dermatosis: case report and review of drug-induced Sweet's syndrome. J Am Acad Dermatol 1996; 34: 918-23
82. Guimera FJ, Carcia-Bustinduy M, Noda A, et al. Diazepam-associated Sweet's syndrome. Int J Dermatol 2000; 39: 795-800
83. Tefany FJ, Georgouras K. A neutrophilic reaction of Sweet's syndrome type associated with the oral contraceptive. Australas J Dermatol 1991; 32: 55-9
84. Mensing H, Kowalzick L. Acute febrile neutrophilic dermatosis (Sweet's syndrome) caused by minocycline. Dermatologica 1991; 182: 43-6
85. Richard MA, Grob JJ, Laurans R, et al. Sweet's syndrome induced by granulocyte colony-stimulating factor in a woman with congenital neutropenia. J Am Acad Dermatol 1996; 35: 629-31
86. Krasovec M, Elsner P, Burg G. Generalized eczematous skin rash possibly due to HMG-CoA reductase inhibitors. Dermatology 1993; 186: 248-52
87. Bircher AJ, Flückiger R, Buchner SA. Eczematous infiltrated plaques to subcutaneous heparin: a type IV allergic reaction. Br J Dermatol 1990; 123: 507-14
88. Whittam LR, Hay RJ, Hughes RAC. Eczematous reactions to human immune globulin. Br J Dermatol 1997; 137: 467-84
89. Bastuji-Garin S, Rzany B, Stern RS, et al. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol 1993; 129: 92-6
90. Weedon D. Cutaneous drug reactions. In: Weedon D, editor. Skin pathology. Edinburgh: Churchill Livingstone, 1997: 559-569
91. Rosado A, Canto G, Veleiro B, et al. Toxic epidermal necrolysis after repeated injections of iohexol. AJR Am J Roentgenol 2001; 176: 262-3
92. Cohen LM, Skopicki DK, Harrist TJ, et al. Noninfectious vesiculobullous and vesiculopustular diseases. In: Elder D, Elenitsas R, Jaworsky C, Johnson B, editors. Lever's histopathology of the skin. 8th ed. Philadelphia: Lippincott-Raven, 1997: 209-252
93. Smoller BR, Kohler S. Subepidermal vesicular dermatitis. In: Barnhill R, Crowson AN, Busam K, Granter S, editors. Textbook of dermatopathology. New York: McGraw-Hill Co, 1998: 147-171
94. Inachi S, Mizutani H, Shimizu M. Epidermal apoptic cell death in erythema multiforme and Stevens-Johnson syndrome. Arch Dermatol 1997; 133: 845-9
95. Le Cleach L, Delaire S, Boumsell L, et al. Blister-fluid T lymphocytes during toxic epidermal necrolysis are functional cytotoxic cells which express human natural killer (NK) inhibitory receptors. Clin Exp Dermatol 2000; 119: 225-30
96. Correia O, Delgado L, Roujeau JC, et al. Soluble interleukin 2 receptor and interleukin alpha in toxic epidermal necrolysis: a comparative analysis of serum and blister fluid samples. Arch Dermatol 2002; 138: 29-32
97. Viard I, Wehrli P, Bullani R, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous imunoglobulin. Science 1998; 282: 490-3
98. Wherli P, Viard I, Bullani R, et al. Death receptors in health and disease. J Invest Dermatol 2000; 115: 141-8
99. Stella M, Cassano P, Bollero D, et al. Toxic epidermal necrolysis treated with intravenous high-dose immunoglobulins: our experience. Dermatology 2001; 203: 45-9
100. Posadas SJ, Padial A, Torres MJ, et al. Delayed reactions to drugs show levels of perforin, granzyme B and Fas-L to be related to disease severity. J Allergy Clin Immunol 2002; 109: 155-61
101. Crowson AN, Magro CM. The role of microvascular injury in the pathogenesis of cutaneous lesions of dermatomyositis. Hum Pathol 1996; 27: 15-9
102. Ringheanu M, Laude TA. Toxic epidermal necrolysis in children: an update. Clin Pediatr (Phila) 2000; 39: 687-94
103. Revuz JE, Foujeau JC. Advances in toxic epidermal necrolysis. Semin Cutan Med Surg 1996; 15: 258-66
104. Rohrer TE, Ahmed R. Toxic epidermal necrolysis. Int J Dermatol 1991; 30: 457-66
105. Smoot III CE. Treatment issues in the care of patients with toxic epidermal necrolysis. Burns 1999; 25: 439-42
106. Halebian PH, Corder VJ, Madden MR, et al. Improved burn center survival of patients with toxic epidermal necrolysis managed without corticosteroids. Ann Surg 1986; 204: 503-12
107. Weston WL, Oranje A, Rasmussen JE, et al. Corticosteroids for erythema multiforme? Pediatr Dermatol 1989; 6: 229-50
108. Kelemen III JJ, Cioffi WG, McManus WF, et al. Burn center care for patients with toxic epidermal necrolysis. J Am Coll Surg 1995, 278
109. Kishimoto K, Imaatsuki K, Akiba H, et al. Subcorneal pustular dermatosis-type IgA pemphigus induced by thiol drugs. Eur J Dermatol 2001; 11: 41-4
110. Brenner S, Bialy-Golan A, Anhalt GJ. Recognition of pemphigus antigens in drug-induced pemphigus vulgaris and pemphigus foliaceous. J Am Acad Dermatol 1997; 36: 919-23
111. Pisani M, Ruocco V. Drug-induced pemphigus. Clin Dermatol 1986; 4: 118-32
112. Ruocco V, Sacerdoti G. Pemphigus and bullous pemphigoid due to drugs. Int J Dermatol 1991; 30: 307-12
113. Bastuji-Garin S, Joly P, Picard-Dahan C, et al. Drugs associated with bullous pemphigoid: a case-control study. Arch Dermatol 1996; 132: 272-6
114. Van Joost T, van't Veen AJ. Drug-induced cicatricial pemphigoid and acquired epidermolysis bullosa. Clin Dermatol 1993; 11: 521-7
115. Alcalay J, David M, Ingber A, et al. Bullous pemphigoid mimicking bullous erythema multiforme: an untoward side effect of penicillins. J Am Acad Dermatol 1988; 18: 345-9
116. Nie Z, Hashimoto K. IgA antibodies of cicatricial pemphigoid sera specifically react with C-terminus of BP180. J Invest Dermatol 1999; 112: 254-5
117. Kirtschig G, Mengel R, Mittag H, et al. Desquamative gingivitis and balanitis: linear IgA disease or cicatricial pemphigoid? Clin Exp Dermatol 1998; 23: 173-7
118. Leonard J, Haffenden GP, Ring NP, et al. Linear IgA disease in adults. Br J Dermatol 1982; 107: 301-16
119. Allen J, Zhou S, Wakelin SH, et al. Linear IgA disease: a report of two dermal binding sera which recognize a pepsin-sensitive epitope (?NC-I domain) of collagen type VII. Br J Dermatol 1997; 137: 526-33
120. Marinkovich MP, Taylor TB, Keene DR, et al. LAD-1, the linear IgA bullous dermatosis autoantigen is a novel 120-kDa anchoring filament protein synthesized by epidermal cells. J Invest Dermatol 1996; 106: 734-8
121. Yawalkar N, Reimers A, Hari Y, et al. Drug-induced linear IgA bullous dermatosis associated with ceftriaxone- and metronidazole-specific T cells. Dermatology 1999; 199: 25-30
122. Nousari HC, Kimyai-Asadi A, Caeiro JP, et al. Clinical, demographic, and immunohistologic features of vancomycin-induced linear IgA bullous disease of the skin: report of 2 cases and review of the literature. Medicine (Baltimore) 1999; 78: 1-8
123. Paul C, Wolkenstein P, Prost C, et al. Drug-induced linear IgA disease: target antigens are heterogeneous. Br J Dermatol 1997; 136: 406-11
124. Wakelin SH, Allen J, Zhou S, et al. Drug-induced linear IgA disease with antibodies to collagen VII. Br J Dermatol 1998; 138: 310-4
125. Acostamadiedo JM, Perniciaro C, Rogers III RS. Phenytoin-induced linear IgA bullous disease. J Am Acad Dermatol 1998; 38: 352-6
126. Camilleri M, Pace JL. Linear IgA bullous dermatosis induced by piroxicam. Eur J Dermatol 1998; 10: 70-2
127. Cerottini J-P, Ricci C, Guggisberg D, et al. Drug-induced linear IgA bullous dermatosis probably induced by furosemide. J Am Acad Dermatol 1999; 41: 103-5
128. Friedman IS, Rudikoff D, Phelps RG, et al. Captopril-triggered linear IgA bullous dermatosis. Int J Dermatol 1998; 37: 608-12
129. Kano Y, Kokaji T, Shiohara T. Linear IgA bullous dermatosis in a patient with acute lymphocytic leukemia: possible involvement of granulocyte clony-stimulating factor. Eur J Dermatol 1999; 9: 122-5
130. Wiadrowski TP, Reid CM. Drug-induced linear IgA bullous disease following antibiotics. Australas J Dermatol 2001; 42: 196-9
131. Konig C, Eickert A, Scharfetter-Kochanek K, et al. Linear IgA bullous dermatosis induced by atorvastatin. J Am Acad Dermatol 2001; 44: 689-92
132. Poh-Fitzpatrick MB. Porphyria, pseudoporphyria, pseudopseudoporphyria...? Arch Dermatol 1986; 122: 403-4
133. Magro CM, Crowson AN. Pseudo-poryphyria cutanea tarda associated with nabumetone (Relafen) therapy. J Cutan Pathol 1999; 26: 42-7
134. Varma S, Lanigan SW. Pseudoporphyria caused by nabumetone. Br J Dermatol 1998; 138: 549-50
135. Tsukazaki N, Watanabe M, Irifune H. Porphyria cutanea tarda and hepatitis C infection. Br J Dermatol 1998; 138: 1015-7
136. Al-Khenaizan S, Schechter JF, Sasseville D. Pseudoporphyria induced by propionic acid derivatives. J Cutan Med Surg 1999; 3: 162-6
137. Le Goff P, Saraux A. Drug-induced lupus. Rev Rhum Engl Ed 1999; 66: 40-5
138. Pramatarov KD. Drug-induced lupus erythematosus. Clin Dermatol 1998; 16: 367-77
139. Crowson AN, Magro CM. Diltiazem and subacute cutaneous lupus erythematosus-like lesions [letter]. N Engl J Med 1995; 333: 1429
140. Goodrich A, Kohn S. Hydrochlorthiazide-induced lupus erythematosus: a new variant? J Am Acad Dermatol 1993; 28: 1001-2
141. Bonsmann G, Schiller M, Luger TA, et al. Terbinafine-induced subacute cutaneous lupus erythematosus. J Am Acad Dermatol 2001; 44: 925-31
142. Murphy M, Barnes L. Terbinafine-induced lupus erythematosus. Br J Dermatol 1998; 138: 708-9
143. Ghate JV, Turner ML, Rudek MA, et al. Drug-induced lupus associated with COL-3. Arch Dermatol 2001; 137: 471-4
144. Rubin RL. Etiology and mechanisms of drug-induced lupus. Curr Opin Rheumatol 1999; 11: 357-63
145. Crosson J, Stillman MT. Minocycline-related lupus erythematosus with associated liver disease. J Am Acad Dermatol 1997; 36: 867-8
146. Magro CM, Crowson AN, Harrist TJ. The use of antibody to C5b-9 in the subclassification of lupus erythematosus. Br J Dermatol 1996; 134: 855-62
147. Mills JA. Systemic lupus erythematosus. N Engl J Med 1994; 330 (26): 1871-9
148. Wollenberg A, Meurer M. Thiazide diuretic-induced subacute cutaneous lupus erythematosus [in German]. Hautarzt 1991; 42: 709-12
149. Gupta AK, Sibbald RG, Knowles SR, et al. Terbinafine therapy may be associated with the development of psoriasis de novo or its exacerbation: four case reports and a review of drug-induced psoriasis. J Am Acad Dermatol 1997; 36: 858-62
150. Webster GF, Knobler RL, Lublin FD, et al. Cutaneous ulcerations and pustular psoriasis flare caused by recombinant interferon beta injections in patients with mutliple sclerosis. J Am Acad Dermatol 1996; 34: 365-7
151. Valance A, Lebrun-Vignes B, Descamps V, et al. Icodextrin cutaneous hypersensitivity: report of 3 psoriasiform cases. Arch Dermatol 2001; 137: 309-10
152. Brenner S, Golan H, Lerman Y. Psoriasiform eruption and anticonvulsant drugs [letter]. Acta Derm Venereol 2000; 80: 382
153. Wolf R, Ruocco V. Triggered psoriasis. Adv Exp Med Biol 1999; 455: 221-5
154. Sigurdsson V, Toonstra J, Hezemans-Boer M, et al. Erythroderma: a clinical and follow-up study of 102 patients, with special emphasis on survival. J Am Acad Dermatol 1996; 35: 53-7
155. Nicolis G, Helwig EB. Exfoliative dermatitis: a clinicopathologic study of 135 patients. Arch Dermatol 1973; 108: 788-97
156. King Jr LE, Dufresne Jr RG, Lovett GL, et al. Erythroderma: review of 82 cases. South Med J 1986; 79: 1210-5
157. Sehgal VN, Srivastava G. Exfoliative dermatitis: a prospective study of 80 patients. Dermatologica 1986; 173: 278-84
158. Botella-Estrada R, Sanmartin O, Oliver V, et al. Erythroderma: a cliniopathological study of 56 cases. Arch Dermatol 1994; 130: 1503-7
159. Sarkar R, Sharma RC, Koranne RV, et al. Erythroderma in children: a clinicopathologic study. J Dermatol 1999; 26: 507-11
160. Pruszkowski A, Bodemer C, Fraitag S, et al. Neonatal and infantile erythrodermas: a retrospective study of 51 patients. Arch Dermatol 2001; 136: 875-80
161. Sanchez NP, Van Hale HM, Su WPD. Clinical and histopathologic spectrum of necrotizing vasculitis. Arch Dermatol 1985; 121: 220-4
162. Jorizzo JL. Classification of vasculitis. J Invest Dermatol 1993; 100: 106S-10S
163. Magro CM, Crowson AN. The cutaneous neutrophilic vascular injury syndromes: a review. Semin Diagn Pathol 2001; 18: 47-58
164. Kaneko K, Igarashi J, Suzuki Y, et al. Carbamazepine-induced thrombocytopenia and leucopenia complicated by Henoch-Schonlein purpura symptoms. Eur J Pediatr 1993; 52: 769-70
165. Kramer KE, Yaar M, Andersen W. Purpuric drug eruption secondary to itraconazole. J Am Acad Dermatol 1997; 37: 944-5
166. Crowson AN, Usmani A, Magro CM, et al. Immunoglobulin-A associated lymphocytic vasculopathy: a clinical and pathological entity resembling pigmentary purpura. J Cutan Pathol 2002; 29: 596-601
167. Chang MW, Miner JE, Moiin A, et al. Iododerma after computed tomographic scan with intravenous radiopaque contrast media. J Am Acad Dermatol 1997; 36: 1014-6
168. Bel S, Bartralot R, Garcia D, et al. Vegentant bromoderma in an infant. Pediatr Dermatol 2001; 18: 336-8
169. Ricci C, Krasovec M, Frenk E. Amiodarone induced iododerma treated by cyclosporine. Ann Dermatol Venereol 1997; 124: 260-3
170. Boudoulas O, Siegle RJ, Grimwood RE. Oidoderma occurring after orally administered iopanoic acid. Arch Dermatol 1987; 123: 387-8
171. Miranda-Romero A, Sanchez-Sambucety P, Esquivias Gomez JI, et al. Vegetating iododerma with fatal outcome. Dermatology 1999; 198: 295-7
172. Soria C, Allegue F, España A, et al. Vegetating iododerma with underlying systemic diseases: report of three cases. J Am Acad Dermatol 1990; 22: 418-22
173. Magro CM, Crowson AN, Mihm MC. Cutaneous manifestations of gastrointestinal disease. In: Elder DE, Johnson BE, Jaworsky C, Elenitsas R, editors. Lever's histopathology of the skin. 8th ed. Philadelphia: JB Lippincott Co, 1997: 353-368
174. Rongioletti F, Semino M, Drago F, et al. Blastomycosis-like pyoderma (pyoderma vegetans) responding to antibiotics and topical disodium chromoglycate. Int J Dermatol 1996; 35: 828-30
175. Rosenberg FR, Einbinder J, Walzer RA, et al. Vegetating idododerma: an immunologic mechanism. Arch Dermatol 1972; 105: 900-5
176. Porters JE, Zantkuyl CF. Ioderma caused by amiodarone [letter]. Arch Dermatol 1975; 111: 1656